Comparative Efficacy and Safety of Epoetin Alfa Vs Desidustat In Chronic Kidney Disease Patients On Maintenance Hemodialysis

ABSTRACT

This study was carried out to compare the efficacy and safety of epoetin alfa vs desidustat (propyl hydroxylase inhibitor) for treatment of anemia in chronic kidney disease (CKD) patients on maintenance hemodialysis. Sixty patients of CKD stage 5 were included in the study undergoing maintenance hemodialysis. These patients were divided randomly into two groups. Group A consists of 30 patients who received epoetin alfa during each dialysis (3 times/week). Group B consisting of 30 patients received desidustat tablet 3 times/week. The change in the haemoglobin level was taken as the main evaluation parameter between epoetin alfa and desidustat groups and measured after three months. The change in haemoglobin level from baseline to 3 months was 1.37 g/dl in epoetin alfa group and 1.53 g/dl in desidustat group. The safety profile of both the drugs was comparable. There were no increased risks seen with desidustat as compared to epoetin alfa. In this study desidustat is found to be more efficacious with equal side effects as compared to epoetin alfa in ckd patients on maintenance hemodialysis.

Keywords: Epoetin alfa, desidustat, ckd, hemodialysis.